Advantages of Biocytogen's Novel Hu-VHH Platform

• The Single VHH (variable heavy domain of heavy chain) is only half the size of scFv (single-chain fragment variable) proteins, enabling better penetration of solid tumors and the blood-brain barrier.
• Based on RenNano, fully human heavy-chain antibodies (HCAbs) or fully human VHH (Hu-VHH) do not require humanization in vitro, resulting in a faster and more cost-effective antibody discovery process.
• It can produce fully human HCAbs with sequence diversity, good affinity, and favorable pharmacokinetic properties.
• The simple structure of functional Hu-VHH facilitates the manufacturing process, which is crucial if the Hu-VHH will be assembled into complex modalities such as a bispecific/multispecific antibody or cell therapy.

Nano 100 Project

Using RenNano, Biocytogen is creating a Hu-VHH antibody library for 100+ high-potential therapeutic targets including tumor-associated antigens, GPCRs, immune checkpoints, cytokine/chemokines, and factors related to neurological diseases.

Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies to combine its large-scale Hu-VHH development abilities with collaborators’ expertise in Hu-VHH-related therapeutics, such as cell therapies, bispecific and multi-specific antibodies, ADCs, and RACs, to develop novel drugs with first-in-class and/or best-in-class potentials.

Off-the-shelf Hu-VHHs Available for Partnership